U.S. Markets open in 1 hr 13 mins
  • Gold

    1,802.60
    +6.30 (+0.35%)
     
  • EUR/USD

    1.1606
    -0.0039 (-0.3366%)
     
  • 10-Yr Bond

    1.6550
    0.0000 (0.00%)
     
  • Vix

    15.83
    +0.82 (+5.46%)
     
  • GBP/USD

    1.3752
    -0.0007 (-0.0523%)
     
  • USD/JPY

    113.6700
    +0.2100 (+0.1851%)
     
  • BTC-USD

    62,953.56
    +2,767.58 (+4.60%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,233.78
    +29.23 (+0.41%)
     
  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     

Infinity Pharma Shows Encouraging Eganelisib/Nivolumab Combo Data In Urothelial Cancer Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Infinity Pharmaceuticals Inc (NASDAQ: INFI) has announced a data presentation from MARIO-275 Phase 2 study evaluating eganelisib combined with Bristol-Myers Squibb's Opdivo (nivolumab) in platinum-refractory, I/O naïve patients with advanced urothelial cancer at the 2021 ASCO Genitourinary Cancers Symposium.

  • In the overall population, the combination of eganelisib with nivolumab demonstrated an increase over nivolumab monotherapy in overall response rate (30% vs. 25%); disease control rate (55% vs. 31%); best responses of complete response (12% vs. 6%); stable disease (24% vs. 6%).

  • Data also showed that the addition of eganelisib on top of 2L standard of care nivolumab was well-tolerated and led to clear benefits for PD-L1 low patients, with an over 85% increase in ORR vs. the control arm. 

  • PD-L1 negative patients demonstrated an extended progression-free survival, reflecting a 46% reduction in the probability of progression of 9.1 weeks on the combination arm versus 7.9 weeks on the control arm.

  • Increased immune activation and decreased immune suppression were observed in combination therapy compared to monotherapy across PD-L1 negative and positive patients.

  • Registration-enabling study in PD-L1 low metastatic urothelial cancer is planned next.

  • Price Action: INFI stock increased 20% at $4.74 in premarket trading on the last check Thursday. 

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.